In the late stages of July and into the early part of this month, previously high-flying growth stocks were repudiated in a big way. The good news is that the sell-off could prove to be a buying opportunity in select growth equities and related ETFs.
July saw a notable shift in U.S. equities. The Magnificent 7 tech sell-off drove a divergence between mega-cap growth stocks and the more value-oriented and smaller large-cap segment of the market.
By Coulter Regal, CFA, Product Manager As U.S. equities climbed, Morningstar's Moat Index kept its value bias, offering a diversifier from concentration risk and the SMID Moat Index shifted from tech to materials and utilities as it seeks valuation opportunities. U.S.
| Insurance Industry | Financials Sector | Thomas J. Nimbley CEO | XSTU Exchange | - ISIN |
| US Country | - Employees | 23 Dec 2024 Last Dividend | - Last Split | - IPO Date |
SHL Telemedicine Ltd. is a pioneering company in the field of personal telemedicine solutions, operating on a global scale with a focus on markets in Israel, Europe, and beyond. Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine leverages telephonic and internet communication technologies to offer innovative healthcare services. The company caters to a diverse client base including patients, health insurance companies, hospitals, clinics, physicians, and other healthcare providers. A hallmark of their operation is the use of personal telemedicine devices that support remote monitoring and diagnostics, fostering a proactive approach to healthcare. Additionally, SHL Telemedicine has established strategic collaboration agreements with prestigious institutions like Mayo Clinic and the Hebrew University of Jerusalem and the Hadassah Medical Center, enhancing its research and development capabilities and reinforcing its commitment to healthcare innovation.